Ligand Pharma (LGNDZ) Stock Price, News & Analysis
Company Description
LGNDZ has declined 57.9% over the past year. Shares last traded at $0.0016.
For FY2025, Ligand Pharma reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.
This page collects what Stock Titan holds for LGNDZ, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Ligand Pharma (LGNDZ) last closed at $0.0016. Over the past 12 months, LGNDZ has lost 57.9%.
LGNDZ Rankings
Latest News
SEC Filings
Ligand Pharma has filed 5 recent SEC filings, including 3 Form 4, 1 Form 144, 1 Form 8-K. The most recent filing was submitted on July 6, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNDZ SEC filings →
Financial Highlights
Ligand Pharma generated $268.1M in revenue in FY2025, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. With a current ratio of 22.23, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Ligand Pharma (LGNDZ) currently stands at 18.8 thousand shares, up 7750.8% from the previous reporting period, representing 0.1% of the shares outstanding. Since September 2025, short interest has increased by 7750.8%.
Days to Cover History
Days to cover for Ligand Pharma (LGNDZ) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.